Table 1.
Multivariable subhazard ratios (HRs) and 95% confidence intervals (CIs) for cause-specific mortality by age, tumor characteristics, and adjuvant therapy among 4,609 women with endometrial carcinoma enrolled in the NRG Oncology/GOG 210 trial, 2003–2011
| Endometrial carcinoma-specific mortality | Non-endometrial carcinoma mortality | |||
|---|---|---|---|---|
| deaths=582 | deaths=272 | |||
| deaths/N | HR (95% CI)1 | deaths/N | HR (95% CI)1 | |
| Age at diagnosis, per year | 1.03 (1.02, 1.04) | 1.08 (1.06, 1.09) | ||
| p-trend | <0.001 | <0.001 | ||
| Stage | ||||
| I | 184/3344 | 1.00 | 170/3344 | 1.00 |
| II | 43/321 | 1.95 (1.25, 3.06) | 23/321 | 1.47 (0.92, 2.35) |
| III | 231/738 | 3.70 (2.69, 5.10) | 58/738 | 1.52 (1.03, 2.24) |
| IV | 124/206 | 7.94 (5.25, 12.00) | 21/206 | 1.82 (1.05, 3.16) |
| p-trend | <0.001 | 0.01 | ||
| Tumor subtype | ||||
| Low-grade endometrioid | 100/2778 | 1.00 | 126/2278 | 1.00 |
| High-grade endometrioid | 116/614 | 3.95 (2.78, 5.62) | 34/614 | 1.16 (0.78, 1.73) |
| Serous | 210/712 | 4.88 (3.45, 6.90) | 71/712 | 1.70 (1.19, 2.43) |
| Carcinosarcoma | 119/331 | 7.52 (5.05, 11.20) | 32/331 | 1.62 (1.05, 2.51) |
| Clear cell | 37/174 | 4.39 (2.51, 7.68) | 9/174 | 0.96 (0.47, 1.96) |
| chi-square p | <0.001 | 0.03 | ||
| Adjuvant therapy | ||||
| None | 155/2619 | 1.00 | 154/2619 | 1.00 |
| Chemotherapy | 241/632 | 1.39 (0.93, 2.07) | 39/632 | 0.56 (0.35, 0.87) |
| Radiation | 85/750 | 1.12 (0.78, 1.61) | 44/750 | 0.73 (0.52, 1.03) |
| Chemotherapy and radiation | 11/573 | 1.18 (0.79, 1.75) | 33/573 | 0.63 (0.41, 0.98) |
| Other | 6/35 | 1.19 (0.35, 4.08) | 2/35 | 0.75 (0.17, 3.23) |
| chi-square p | 0.61 | 0.06 | ||
1
HRs from Fine and Gray semi-proportional competing risk model adjusted for age (continuous), stage (I, II, III, IV), tumor subtype (low-grade endometrioid, high-grade endometrioid, serous, carcinosarcoma, clear cell), adjuvant therapy (none, chemotherapy, radiation, chemotherapy plus radiation, unknown)